Skip to content
Shameless Cloning

Search Shameless Cloning

Search superinvestors, stocks, insiders and members of Congress

Q2 2026 13F · SEC CIK 1744967

Samsara Biocapital, LLC

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value
$1.2B
Reported positions
24
Top holdings a year, 3 yrs
+32.2%
Assets under management
$2.2B

Samsara Biocapital, LLC is a hedge fund that reported 24 positions worth $1.2B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Scholar Rock Hldg Corp (SRRK, 31.2%), Alumis Inc Com (ALMS, 14.7%), Mineralys Therapeutics Inc (MLYS, 13.0%). A portfolio copying its top holdings returned 32.2% a year over the last 3 years, against 20.4% for the S&P 500.

Samsara Biocapital, LLC holdings all 24 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Samsara Biocapital, LLC 13F holdings
Stock% of 13F valueShare changeReported value
SRRKScholar Rock Hldg Corp31.2%+0.0%$379.4M
ALMSAlumis Inc Com14.7%+0.0%$178.6M
MLYSMineralys Therapeutics Inc13.0%+0.0%$158.4M
SEPNSepterna, Inc.8.7%+0.0%$105.5M
ALMRAlamar Biosciences Inc5.5%—$67.2M
NGNENeurogene Inc4.4%+0.0%$54.0M
482929106Kalaris Therapeutics Inc Com4.3%-0.5%$52.4M
SGPSpyglass Pharma Inc3.9%+0.0%$47.0M
STROSutro Biopharma Inc2.9%+0.0%$35.3M
IVAInventiva SACA2.0%+21.6%$23.9M
008064206Jade Biosciences Inc1.3%-24.0%$16.4M
PBLSParabilis Medicines, Inc.1.3%—$15.2M
VTVTVtv Therapeutics Inc0.9%+0.0%$11.2M
AQSTAquestive Therapeutics Inc0.9%+0.0%$10.4M
NKTXNkarta Inc0.8%+0.0%$9.9M
ARTVArtiva Biotherapeutics Inc0.8%—$9.3M
RANIRani Therapeutics Holdings Inc0.6%+22.0%$7.9M
AGMBAgomab Therapeutics NV0.6%+0.0%$7.8M
ABVXAbivax SA0.6%-2.6%$7.3M
XFORX4 Pharmaceuticals Inc0.5%-23.8%$6.5M
ELOXEloxx Pharmaceuticals Inc0.5%—$5.6M
CHRSCoherus Oncology Inc0.4%+0.0%$4.8M
UPBUpstream Bio Inc0.2%-51.9%$2.4M
GOSSGossamer Bio Inc0.1%+0.0%$1.2M

What Samsara Biocapital, LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Added to

Reduced

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year
+79.7% /yr
S&P 500 +20.1%
3 years
+32.2% /yr
S&P 500 +20.4%
5 years
+12.9% /yr
S&P 500 +11.6%

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter13F valuePositions
Q2 2026$1.2B24
Q1 2026$1.0B22
Q4 2025$969.3M21
Q3 2025$765.9M27
Q2 2025$488.9M29
Q1 2025$560.8M37
Q4 2024$728.6M43
Q3 2024$520.3M42
Q2 2024$477.8M40
Q1 2024$646.4M39
Q4 2023$642.8M41
Q3 2023$326.7M41

Questions about Samsara Biocapital, LLC's portfolio

What stocks does Samsara Biocapital, LLC own?

Samsara Biocapital, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 24 positions worth $1.2B. The largest are Scholar Rock Hldg Corp (SRRK) at 31.2%, Alumis Inc Com (ALMS) at 14.7%, Mineralys Therapeutics Inc (MLYS) at 13.0%, Septerna, Inc. (SEPN) at 8.7% and Alamar Biosciences Inc (ALMR) at 5.5%.

What did Samsara Biocapital, LLC buy last quarter?

In Q2 2026, Samsara Biocapital, LLC added a new position in Alamar Biosciences Inc (ALMR), a new position in Parabilis Medicines, Inc. (PBLS), a new position in Artiva Biotherapeutics Inc (ARTV), a new position in Eloxx Pharmaceuticals Inc (ELOX), Rani Therapeutics Holdings Inc (RANI) (+22.0% shares) and Inventiva SACA (IVA) (+21.6% shares), compared with its Q1 2026 filing.

What did Samsara Biocapital, LLC sell last quarter?

In Q2 2026, Samsara Biocapital, LLC sold all of Arcellx Inc (ACLX), sold all of Palvella Therapeutics Inc (PVLA), Upstream Bio Inc (UPB) (-51.9% shares), Jade Biosciences Inc (-24.0% shares) and X4 Pharmaceuticals Inc (XFOR) (-23.8% shares), compared with its Q1 2026 filing.

How has Samsara Biocapital, LLC's portfolio performed?

A portfolio copying Samsara Biocapital, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +32.2% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +79.7% against +20.1%. Over 5 years: +12.9% a year against +11.6%.

When is Samsara Biocapital, LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. Samsara Biocapital, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Samsara Biocapital, LLC manage?

Samsara Biocapital, LLC reported $2.2B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $1.2B.